摘要
目的:探讨多药耐药P-糖蛋白(P-glycoprotein,P-gp)、谷胱甘肽转移酶(glutathione-S-trannsferaseπ,GST-π)和拓扑异构酶(DNA topoisomeraseⅡ,TopoⅡ)在大肠癌组织中的表达及临床意义。方法:应用免疫组化SP法联合检测P-gp、GST-π和TopoⅡ在84例大肠癌组织和20例正常大肠黏膜组织中的表达,并结合临床病理参数进行分析。结果:P-gp、GST-π在大肠癌组织中的表达率分别为71.4%(60/84)和75.0%(63/84),高于正常大肠黏膜组织(8/20和11/20),χ2值分别为6.91和3.14,P均<0.05;P-gp表达强度与临床分期相关,高分期P-gp表达(86.7%、39/45)较低分期(65.5%、19/29)高,χ2=5.28,P<0.05;TopoⅡ在大肠癌组织中的阳性率为45.3%(38/84),低于正常大肠黏膜组织65%(13/20),χ2=0.382,P>0.05;高、中和低分化腺癌P-gp(87.5%、80.7%和54.5%)和GST-π(87.5%、82.5%和54.5%)的表达率由高到低;TopoⅡ的表达率由低到高(37.5%、45.6%和63.6%)。淋巴结转移组P-gp和GST-π的表达显著高于无淋巴结转移组,P<0.05。结论:P-gp、GST-π和TopoⅡ均在大肠癌原发性多药耐药中起重要作用。联合检测P-gp、GST-π和TopoⅡ对于大肠癌化疗方案选择具有一定的指导意义。
To study the clinical significance of P-glycoprotein （P-gp）, glutathione-S-rannsferaseπ （GST-n） and DNA topoisomerase Ⅱ （Topo ） expressions in colorectal carcinoma tissue. METHODS： The expressions of P-gp, GST-π and Topo Ⅱ in 84 cases of colorectal carcinoma and 20 cases of normal tissues were detected by SP immunohistochemieal technique, and its correlation with clinical pathologic characteristics of carcinoma was explored. RESULTS： The expression rates of P-gp （71.4%, 60/84） and GST-π （75%, 63/84） in colorectal carcinoma were all higher than those in normal tissues （ X^2 was 6.91 and 3.14, P〈0.05）, while the expression rate of Topo Ⅱ （45.3%, 38/84） in colorectal carcinoma was lower, X^2=382, P〉0.05. The expression of P-gp was associated with clinical stage of tumor. The expression rate of P-gp on high clinical stage was 86.7%（39/45） and higher than that of low clinial stage （ 65.5 %, 19/29 ）, ）C = 5.28, P〈 0.05. The expression rates of P-gp and GST-n were 87.5%, 80.7%, 54.5% and 87.5%, 82.5%, 54.5% in well-differentiated adencarcinoma, moderately differentiated adencarcinoma and poorly differentiated adenocarcinoma respectively. The expression arets of Topo Ⅱ were 37.5%, 45.6% and 63.6%. The expression rates of P-gp （87.5%, 80.7% and 54.5%） and GST-π （87.5%, 82.5% and 54.5%） in group with lymph metastasis were significantly higher than those in group without lymph node metastasis （37.5%, 45.6% and 63.6%）, P%0.05. CONCLUSIONS： P-gp, GST-π, and Topo II play important roles in the primary MDR of colorectal carcinoma. The determination of P-gp, GST-π and Topo Ⅱ may be useful for the estimation of prognosis and the establishment of chemical thera- py regimen in colorectal carcinoma.
出处
《中华肿瘤防治杂志》
CAS
2007年第15期1152-1155,共4页
Chinese Journal of Cancer Prevention and Treatment
